Nulojix®
Understanding Nulojix®
Nulojix® (belatacept) is an immunosuppressant used to prevent organ rejection in patients who have received a kidney transplant. It works by blocking T-cell activation, which helps prevent the immune system from attacking the transplanted organ. By selectively inhibiting immune responses, Nulojix® helps improve long-term transplant outcomes while reducing the need for traditional immunosuppressive therapies.
How Nulojix® Works:
- Blocks T-cell activation to prevent immune rejection of the transplanted kidney.
- Helps maintain long-term kidney function with a targeted immunosuppressive approach.
- Reduces dependence on traditional immunosuppressants, which may have additional side effects.
FDA Approval:
- Nulojix® (belatacept): Approved on June 15, 2011
For more information, please visit the Nulojix® patient website and speak with your healthcare provider to determine if Nulojix® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Bristol-Myers Squibb (BMS) |
CLASS: Selective T-Cell Costimulation Blocker (Immunosuppressant) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Day one, day five, week two, week four then every four weeks |
Length of infusion: About 30 mins |
FOR MORE INFORMATION: |
Related drugs
